Investigation of Cardiovascular Disease and Metabolic Syndrome Risk with Copeptin in Psoriasis Patients: A Case-Control Study.

MLA

Agirgol, Senay, et al. “Investigation of Cardiovascular Disease and Metabolic Syndrome Risk with Copeptin in Psoriasis Patients: A Case-Control Study.” Medical Bulletin of Haseki / Haseki Tip Bulteni, vol. 60, no. 3, May 2022, pp. 270–75. EBSCOhost, https://doi.org/10.4274/haseki.galenos.2022.7694.

APA

Agirgol, S., Akbulut, T. O., Demir, F. T., Cakir, E., Gumus, A., Agirgol, M., Turkoglu, Z., & Caytemel, C. (2022). Investigation of Cardiovascular Disease and Metabolic Syndrome Risk with Copeptin in Psoriasis Patients: A Case-Control Study. Medical Bulletin of Haseki / Haseki Tip Bulteni, 60(3), 270–275. https://doi.org/10.4274/haseki.galenos.2022.7694

Chicago

Agirgol, Senay, Tugba Ozkok Akbulut, Filiz Topaloglu Demir, Evrim Cakir, Alper Gumus, Muharrem Agirgol, Zafer Turkoglu, and Ceyda Caytemel. 2022. “Investigation of Cardiovascular Disease and Metabolic Syndrome Risk with Copeptin in Psoriasis Patients: A Case-Control Study.” Medical Bulletin of Haseki / Haseki Tip Bulteni 60 (3): 270–75. doi:10.4274/haseki.galenos.2022.7694.